We found that high ACE2 expression levels lead to high risk of COVID‐19 infection and poor prognosis of breast invasive carcinoma (BRCA), while better prognosis in ovarian serous cystadenocarcinoma (OV) patient cohorts. Here, ACE2 is linked to ovarian serous cystadenocarcinoma.